市場調查報告書
商品編碼
1535214
ALK檢驗市場:各市場區隔規模,佔有率,法律規章,償付,2033年為止的預測ALK Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
間變性淋巴瘤受體酪胺酸激?(ALK)基因檢測用於檢測非小細胞肺癌腫瘤細胞內的基因重排,其結果可用於治療非小細胞肺癌(NSCLC)可能帶來治療方法為了
ALK 是受體酪胺酸激?家族的成員,是控制細胞增生和分化的關鍵因子。大多數 ALK 基因突變都是易位,即 ALK 基因與其他基因結合形成融合癌基因。 ALK 基因檢測用於檢測非小細胞肺癌腫瘤細胞內的基因重排,其結果可指導非小細胞肺癌 (NSCLC) 的治療。
本報告提供全球ALK檢驗市場相關資料詳細考察,提供市場上競爭情形,SWOT分析,到2033年為止的市場預測,地區,各國的趨勢等資訊。
ALK Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative and qualitative market trends within In Vitro Diagnostics therapeutic area.
Anaplastic Lymphoma Receptor Tyrosine Kinase (ALK) gene tests are carried out to detect gene rearrangements within non-small cell lung cancer tumor cells; the outcome of which may guide therapies to treat non-small cell lung cancer (NSCLC).
ALK is a member of the receptor tyrosine kinase family and a major factor in regulating cellular proliferation and differentiation. The majority of ALK mutations are translocations, whereby the ALK gene is partnered with other gene to form a fusion oncogene. ALK gene tests are carried out to detect gene rearrangements within non-small cell lung cancer tumor cells, the outcome of which may guide therapies to treat non-small cell lung cancer (NSCLC).
Each of the covered 39 countries color-coded and fully-sourced market model is equipped with epidemiology-based indications. The interactive excel deliverable covers value, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are:
Currently marketed ALK Tests and evolving competitive landscape:
Global, Regional and Country level market specific insights:
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: F. Hoffmann-La Roche Ltd, Agilent Technologies Inc, Integrated DNA Technologies Inc, Biocare Medical LLC, Thermo Fisher Scientific Inc, Cancer Diagnostics, Inc., Abbott Laboratories, Sysmex Corp, ZytoVision GmbH, Qiagen NV, Bio-Rad Laboratories Inc, Illumina Inc, New England Biolabs Inc, EntroGen, Inc, Amoy Diagnostics Co Ltd, HLB PanaGene Co Ltd, and Others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.
This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
The model will enable you to -